Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (612)	5/6/2001 1:13:26 AM
From: keokalani'nui	Read Replies (4) \| Respond to of 1784

Tuck: Thanks for the MCLS link. I did see the earlier one. BTW, I went back through all the Trickle posts yesterday (very refreshing) and was shocked to see I was the one who argued for including MCLS in the watch list. Oy, my memory. DPII says systems sales are slower than expected. PCOP said their organic growth Y-Y is not much more than 15%. MDS's top line growth is in high single digits. A lot of trickle stocks just aren't growing all that fast. You look at Quiagen, Waters, Techne, Caliper (and Caliper is different since it is still basically in the feasibility stage), though growing faster, and have to conclude they are all expensive. Don't NBIX and CALP have about the same market cap? In real life, not much of a choice when you look at it that way, to me. Only trickle I own is MDS, and it is expensive too. Would like to own Techne at about $18, but what are the chances. Isn't Red Rocks on the way to Mojave? Used to pass that way long ago. Wilder